JP2012501454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501454A5 JP2012501454A5 JP2011525253A JP2011525253A JP2012501454A5 JP 2012501454 A5 JP2012501454 A5 JP 2012501454A5 JP 2011525253 A JP2011525253 A JP 2011525253A JP 2011525253 A JP2011525253 A JP 2011525253A JP 2012501454 A5 JP2012501454 A5 JP 2012501454A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- apo
- apolipoprotein
- alt
- uln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010071619 Apolipoproteins Proteins 0.000 claims 8
- 102000007592 Apolipoproteins Human genes 0.000 claims 8
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims 7
- 101700077954 APOA1 Proteins 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 3
- 210000001124 Body Fluids Anatomy 0.000 claims 2
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 231100000595 drug-induced hepatitis Toxicity 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- 102100001085 APOB Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 claims 1
- 102400000352 Apolipoprotein B-48 Human genes 0.000 claims 1
- 108010004994 Apolipoprotein B-48 Proteins 0.000 claims 1
- 108010076807 Apolipoprotein C-I Proteins 0.000 claims 1
- 102000011772 Apolipoprotein C-I Human genes 0.000 claims 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 claims 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims 1
- 102000030703 Apolipoprotein C-III Human genes 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000003097 Mucus Anatomy 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 210000003296 Saliva Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 210000002700 Urine Anatomy 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9268608P | 2008-08-28 | 2008-08-28 | |
| US61/092,686 | 2008-08-28 | ||
| PCT/US2009/055430 WO2010025410A2 (fr) | 2008-08-28 | 2009-08-28 | Procédé d'analyse permettant d'identifier des patients risquant des complications hépatologiques indésirables pathologiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012501454A JP2012501454A (ja) | 2012-01-19 |
| JP2012501454A5 true JP2012501454A5 (fr) | 2012-10-11 |
Family
ID=41722327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525253A Pending JP2012501454A (ja) | 2008-08-28 | 2009-08-28 | 肝臓病学的有害事象のリスクのある患者を同定するためのスクリーニング法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2342569A4 (fr) |
| JP (1) | JP2012501454A (fr) |
| CN (1) | CN102257389A (fr) |
| CA (1) | CA2735582A1 (fr) |
| WO (1) | WO2010025410A2 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011352073B2 (en) * | 2010-12-30 | 2015-12-24 | Sami Labs Limited | Hepatoprotectant activity of garcinol |
| WO2012122024A2 (fr) * | 2011-03-04 | 2012-09-13 | Russell Medford | Procédé de criblage pour identifier des patients à risque de lésion hépatique induite par médicament |
| CN103376323A (zh) * | 2012-04-25 | 2013-10-30 | 中国科学院上海生命科学研究院 | 载脂蛋白c-iii作为肥胖型糖尿病标志物的应用 |
| CN103063848B (zh) * | 2012-12-26 | 2015-06-03 | 潍坊三维生物工程集团有限公司 | 一种用免疫比浊法测定载脂蛋白c2的试剂盒 |
| WO2018109004A1 (fr) * | 2016-12-14 | 2018-06-21 | Roche Diagnostics Gmbh | Détermination d'interférents dans un échantillon |
| EP3373012A1 (fr) | 2017-03-07 | 2018-09-12 | Biopredictive | Procédé de diagnostic d'une lésion hépatique induite par un médicament |
| CN110780071A (zh) * | 2019-11-11 | 2020-02-11 | 彭涛 | 一种乙肝相关肝细胞癌的预后检测试剂盒 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5500375A (en) | 1993-04-13 | 1996-03-19 | Serex, Inc. | Integrated packaging-holder device for immunochromatographic assays in flow-through or dipstick formats |
| EP0710288B1 (fr) * | 1993-06-10 | 2006-04-05 | Genetic Therapy, Inc. | Vecteurs adenoviraux pour le traitement de l'hemophilie |
| US6107045A (en) * | 1994-06-30 | 2000-08-22 | Oklahoma Medical Research Foundation | Antibodies to lipoproteins and apolipoproteins and methods of use thereof |
| AU762931B2 (en) * | 1999-03-16 | 2003-07-10 | Serex, Inc. | Method and device for detection of Apo A, Apo B and the ratio thereof in saliva |
| JP2004123716A (ja) * | 2002-08-06 | 2004-04-22 | Mitsubishi Pharma Corp | 化学物質に起因する肝障害の予防及び／又は治療のための医薬 |
| ATE462001T1 (de) * | 2002-12-24 | 2010-04-15 | Nitto Boseki Co Ltd | Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit |
| WO2005002505A2 (fr) * | 2003-05-23 | 2005-01-13 | Johns Hopkins University | Apoptose induite par l'apolipoproteine c-1 |
| FR2870348B1 (fr) * | 2004-05-14 | 2010-08-27 | Univ Angers | Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet |
| US7856319B2 (en) * | 2005-02-03 | 2010-12-21 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of alcoholic steato-hepatitis using biochemical markers |
| US7860656B2 (en) * | 2005-02-03 | 2010-12-28 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of hepatic steatosis using biochemical markers |
| EP1726962A1 (fr) * | 2005-05-24 | 2006-11-29 | Leiden University Medical Center | Concentrations plasmatiques de lipoprotéine E pour surveiller et réduire le risque des maladies cardiovasculaires |
-
2009
- 2009-08-28 EP EP09810686A patent/EP2342569A4/fr not_active Withdrawn
- 2009-08-28 WO PCT/US2009/055430 patent/WO2010025410A2/fr active Application Filing
- 2009-08-28 CA CA2735582A patent/CA2735582A1/fr not_active Abandoned
- 2009-08-28 JP JP2011525253A patent/JP2012501454A/ja active Pending
- 2009-08-28 CN CN2009801437323A patent/CN102257389A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501454A5 (fr) | ||
| de Mello et al. | Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action | |
| Koutroubakis et al. | Serum laminin and collagen IV in inflammatory bowel disease | |
| Chatterjee et al. | An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer | |
| Lu et al. | A phase I dose escalation study demonstrates quercetin safety and explores potential for bioflavonoid antivirals in patients with chronic hepatitis C | |
| Amigo et al. | Cholecystectomy increases hepatic triglyceride content and very‐low‐density lipoproteins production in mice | |
| Yu et al. | The study of efficacy of lamivudine in patients with severe acute hepatitis B | |
| Ogasawara et al. | Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters | |
| Wong et al. | Genetic polymorphisms of adiponectin and tumor necrosis factor‐alpha and nonalcoholic fatty liver disease in Chinese people | |
| Lendvai et al. | Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies | |
| Lopes et al. | Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia | |
| RU2012102399A (ru) | Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови | |
| Goyal et al. | HBsAg level as predictor of liver fibrosis in HBeAg positive patients with chronic hepatitis B virus infection | |
| JP2014526676A5 (fr) | ||
| He et al. | Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy | |
| Yun et al. | Hepatic steatosis and fibrosis in young men with treatment‐naïve chronic hepatitis B | |
| Xia et al. | Correlations of creatine and six related pyrimidine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients | |
| Castro et al. | Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease | |
| Patel et al. | Open‐label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C | |
| Shoaib et al. | Dyslipidemia and impaired liver function biomarkers in patients with hepatitis B liver cirrhosis | |
| Jang et al. | Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents | |
| CN109459565B (zh) | 人血清C4BP-a蛋白作为预测氯吡格雷抵抗的生物标志物及其临床应用 | |
| Chalupa et al. | Effect of antiviral treatment of chronic hepatitis C on the frequency of regulatory T cells, T‐cell activation, and serum levels of TGF‐beta | |
| Bashir et al. | Association of biochemical markers, hepatitis C virus and diabetes mellitus in Pakistani males | |
| Iwata et al. | Long-term outcome of surgical treatment for non-small cell lung cancer with comorbid liver cirrhosis |